Article
Cardiac & Cardiovascular Systems
Zaki Al-Yafeai, Alexander Carvajal-Gonzalez, Hamzah Abduljabar, Muhammed Arvas, Shaan Patel, Neev Patel
Summary: This study comprehensively evaluated the cardiovascular complications of the newly FDA-approved anti-multiple sclerosis (MS) modifying therapies. CD20 and CD25 inhibitors were significantly associated with cardiovascular adverse events, while S1PR agonists showed fewer cardiac complications. These findings are important for personalized prescribing of MS agents based on the patient's cardiovascular profile.
INTERNATIONAL JOURNAL OF CARDIOLOGY
(2022)
Article
Immunology
Christina Noll, Michael Hiltensperger, Lilian Aly, Rebecca Wicklein, Ali Maisam Afzali, Christian Mardin, Christiane Gasperi, Achim Berthele, Bernhard Hemmer, Thomas Korn, Benjamin Knier
Summary: This study found that rarefication of the retinal vasculature during RRMS is associated with higher frequencies of activated B cells and higher levels of pro-inflammatory cytokines in the cerebrospinal fluid. Furthermore, vessel loss in the retina is linked to future disability worsening.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Health Care Sciences & Services
Viviana Nociti, Marina Romozzi, Massimiliano Mirabella
Summary: Multiple sclerosis (MS) is a complex disease with broad individual and interindividual heterogeneity. Standardization of characteristics in individual patients has been difficult, but easily detectable molecular biomarkers can provide a personalized therapy approach.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Article
Immunology
Igal Rosenstein, Sofia Rasch, Markus Axelsson, Lenka Novakova, Kaj Blennow, Henrik Zetterberg, Jan Lycke
Summary: This study suggests that determination of intrathecal immunoglobulin M synthesis (ITMS) and neurofilament light concentration in cerebrospinal fluid (CSF) can be useful biomarkers for predicting disease severity and disability in relapsing-remitting multiple sclerosis (RRMS). The combination of ITMS with CSF neurofilament light (cNfL) shows a stronger predictive value.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Haoyang Duan, Yuling Jing, Yinghua Li, Yawen Lian, Jianfang Li, Zhenlan Li
Summary: Multiple sclerosis is a slowly progressive disease that can be delayed by immunosuppressants and other drugs, but patients usually experience various neurological deficit symptoms. Professional rehabilitation treatment can reduce dysfunction, improve neurological function, and reduce burdens. New rehabilitation technologies have further established the advantages of rehabilitation therapy in multiple sclerosis treatment.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Multidisciplinary Sciences
Eoin F. McKinney, Iona Cuthbertson, Kristina M. Harris, Dawn E. Smilek, Christopher Connor, Giulia Manferrari, Edward J. Carr, Scott S. Zamvil, Kenneth G. C. Smith
Summary: Improving clinical outcomes in patients with multiple sclerosis requires a better understanding of the immunological mechanisms driving recurrent demyelination and better means of predicting future disease course. Identifying biomarkers and developing better therapeutics is crucial for enhancing treatment effectiveness in MS.
NATURE COMMUNICATIONS
(2021)
Article
Biochemistry & Molecular Biology
Oliver Neuhaus, Wolfgang Koehler, Florian Then Bergh, Wolfgang Kristoferitsch, Juergen Faiss, Thorsten Rosenkranz, Dirk Reske, Robert Patejdl, Hans-Peter Hartung, Uwe K. Zettl
Summary: This study aimed to investigate the correlation between clinical, neuropsychological, and immunological parameters in RRMS patients with fatigue before and during treatment with GA. After 12 months of treatment, 13 patients showed improvement in all three fatigue assessment scales, while 5 patients deteriorated and 7 patients showed inconsistent effects. Fatigue and overall quality of life improved, but no clear correlation between clinical and molecular effects of GA was found in RRMS patients with fatigue.
Article
Immunology
Mariam F. Farid, Yara S. Abouelela, Noha A. E. Yasin, Mohamed R. Mousa, Marwa A. Ibrahim, Abdelbary Prince, Hamdy Rizk
Summary: The study revealed that platelet-rich plasma (PRP) had significant therapeutic effects on multiple sclerosis (MS) in cats, improving motor function and reducing lesions. This method was proven to be effective, safe, and promising for MS treatment.
INFLAMMATION AND REGENERATION
(2022)
Article
Clinical Neurology
Joakim Bergman, Joachim Burman, Tommy Bergenheim, Anders Svenningsson
Summary: The study evaluated the effect of intrathecally delivered rituximab on PMS and found that it was well tolerated but did not halt disease progression.
JOURNAL OF NEUROLOGY
(2021)
Article
Biochemistry & Molecular Biology
Pasquale Picone, Domenico Nuzzo
Summary: In recent years, studies have shown that mitochondrial aberration plays a crucial role in mediating axonal degeneration in Multiple Sclerosis (MS), along with inflammation and demyelination. This has led to the recognition of mitochondria as a potential therapeutic target for MS. Mitochondrial transplantation has emerged as a new approach for treating various diseases, including neurodegenerative diseases. In this hypothesis, the authors propose mitochondrial transplantation as a new, potentially applicable strategy to counteract axonal degeneration in multiple sclerosis.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Biochemistry & Molecular Biology
Nik Krajnc, Thomas Berger, Gabriel Bsteh
Summary: Disability in multiple sclerosis primarily occurs in the progressive forms of the disease, and developing effective drugs to delay disability progression in progressive MS has proven challenging. While some disease-modifying treatments are approved for progressive multiple sclerosis, their effects are moderate and limited mainly to patients with signs of disease activity. The lack of sensitive outcome measures and questions about clinical relevance may explain the challenges faced in clinical trials for progressive multiple sclerosis.
Article
Medicine, General & Internal
Marie Suesse, Franz Felix Konen, Philipp Schwenkenbecher, Kathrin Budde, Matthias Nauck, Matthias Grothe, Malte Johannes Hannich, Thomas Skripuletz
Summary: This observational study investigated the effects of different disease-modifying therapies (DMT) on the humoral intrathecal immune response in the cerebrospinal fluid (CSF) of multiple sclerosis (MS) patients. The results showed that highly effective DMT significantly reduced the concentrations of FLC kappa and IgG in the CSF, which may contribute to an anti-inflammatory effect in the central nervous system (CNS). There was no difference in the appearance of CSF-specific oligoclonal bands.
Article
Immunology
Aigli G. Vakrakou, Maria-Evgenia Brinia, Anastasia Alexaki, Evangelos Koumasopoulos, Panos Stathopoulos, Maria-Eleftheria Evangelopoulos, Leonidas Stefanis, Christine Stadelmann-Nessler, Constantinos Kilidireas
Summary: The expanded treatment landscape in relapsing-remitting MS has provided highly effective treatment options, but also increased complexity in managing disease- or drug-related events. Proper decision-making requires thorough understanding of MS immunobiology and underlying mechanisms. The immune system is highly adaptable, but treatments can have harmful effects. Clinicians need to make appropriate clinical decisions for atypical relapses and consider switching therapies for the multiple faces of MS.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Article
Clinical Neurology
Brit Ellen Rod, Oivind Torkildsen, Kjell-Morten Myhr, Lars Bo, Stig Wergeland
Summary: Our study found minimal transfer of rituximab into breast milk in nursing mothers, and the levels of rituximab in infant serum were difficult to detect. The B cell counts in infants were unaffected.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
(2023)
Article
Clinical Neurology
Igal Rosenstein, Markus Axelsson, Lenka Novakova, Clas Malmestroem, Kaj Blennow, Henrik Zetterberg, Jan Lycke
Summary: While KFLC index is a useful diagnostic biomarker in multiple sclerosis (MS), its prognostic properties are less explored. This study found that high baseline KFLC index is predictive of PIRA, evidence of disease activity (EDA-3), and overall worse prognosis in MS.
JOURNAL OF NEUROLOGY
(2023)
Article
Pharmacology & Pharmacy
Paul A. Frohna, Anoshie Ratnayake, Nick Doerr, Asjad Basheer, Laith Q. Al-Mawsawi, Woo Jae Kim, Juan C. Zapata, Xiaorong Wu, Thomas A. Waldmann, Nazli Azimi, Yutaka Tagaya
JOURNAL OF CLINICAL PHARMACOLOGY
(2020)
Article
Gastroenterology & Hepatology
Cezary Ciszewski, Valentina Discepolo, Alain Pacis, Nick Doerr, Olivier Tastet, Toufic Mayassi, Mariantonia Maglio, Asjad Basheer, Laith Q. Al-Mawsawi, Peter H. R. Green, Renata Auricchio, Riccardo Troncone, Thomas A. Waldmann, Nazli Azimi, Yutaka Tagaya, Luis B. Barreiro, Bana Jabri
Article
Cell Biology
Sigrid Dubois, Lionel Feigenbaum, Thomas A. Waldmann, Jurgen R. Mueller
CELLULAR IMMUNOLOGY
(2020)
Review
Immunology
Thomas A. Waldmann, Milos D. Miljkovic, Kevin C. Conlon
JOURNAL OF EXPERIMENTAL MEDICINE
(2020)
Article
Multidisciplinary Sciences
Olga M. Anton, Mary E. Peterson, Michael J. Hollander, David W. Dorward, Gunjan Arora, Javier Traba, Sumati Rajagopalan, Erik L. Snapp, K. Christopher Garcia, Thomas A. Waldmann, Eric O. Long
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2020)
Article
Oncology
Anusara Daenthanasanmak, Yuquan Lin, Meili Zhang, Bonita R. Bryant, Michael N. Petrus, Richard N. Bamford, Craig J. Thomas, Milos D. Miljkovic, Kevin C. Conlon, Thomas A. Waldmann
Summary: Adult T-cell leukemia (ATL) is an aggressive malignancy caused by HTLV-1, with potential therapeutic benefits in targeting the JAK/STAT and PI3K/AKT/mTOR pathways. Combination treatment of Upadacitinib with mTOR inhibitors shows promising anti-proliferative effects in ATL cell lines and in reducing tumor growth in mice, providing a new direction for ATL treatment.
TRANSLATIONAL ONCOLOGY
(2021)
Article
Multidisciplinary Sciences
Yunlong He, Nagesh Pasupala, Huijun Zhi, Batsuhk Dorjbal, Imran Hussain, Hsiu-Ming Shih, Sharmistha Bhattacharyya, Roopa Biswas, Milos Miljkovic, Oliver John Semmes, Thomas A. Waldmann, Andrew L. Snow, Chou-Zen Giam
Summary: Constitutive NF-kappa B activation induces senescence through R-loop accumulation and DNA double-strand breaks, while ATL cells exhibit deficiencies in TC-NER endonucleases and accumulate R-loops. These vulnerabilities may serve as potential targets for ATL treatment.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Letter
Biophysics
P. Stathopoulos, K. Leger, M. Foege, A. Lutterotti, A. Mueller, U. Schanz, I. Jelcic, R. Martin
BONE MARROW TRANSPLANTATION
(2021)
Review
Immunology
Javier Traba, Michael N. Sack, Thomas A. Waldmann, Olga M. Anton
Summary: This article discusses the main effects of the tumor microenvironment (TME) on the metabolism and function of immune cells, and reviews emerging strategies to boost immune cell metabolism for promoting anti-tumor effects, either as monotherapies or in combination with conventional chemotherapy for optimizing cancer treatment.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Sigrid P. Dubois, Milos D. Miljkovic, Thomas A. Fleisher, Stefania Pittaluga, Jennifer Hsu-Albert, Bonita R. Bryant, Michael N. Petrus, Liyanage P. Perera, Jurgen R. Muller, Joanna H. Shih, Thomas A. Waldmann, Kevin C. Conlon
Summary: The study demonstrated that administering IL-15 as CIV-5 significantly expanded NK cells with increased cytotoxic functions. There were no dose-limiting toxicities in the CIV-5 regimen, and a substantial increase in CD8(+) T cells was observed.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Biochemistry & Molecular Biology
Marcia Bellon, Izabela Bialuk, Veronica Galli, Xue-Tao Bai, Lourdes Farre, Achilea Bittencourt, Ambroise Marcais, Michael N. Petrus, Lee Ratner, Thomas A. Waldmann, Vahid Asnafi, Antoine Gessain, Masao Matsuoka, Genoveffa Franchini, Olivier Hermine, Toshiki Watanabe, Christophe Nicot
Summary: The epigenetic alteration of FHIT was found to be specifically present in chronic and acute ATL patients, while absent in asymptomatic HTLV-I carriers and TSP/HAM patients. The extent of FHIT methylation in ATL patients was quantitatively comparable in virus-infected and non-infected cells. Results suggest that germinal epigenetic mutation of FHIT may predispose individuals to the development of ATL diseases.
Article
Biochemistry & Molecular Biology
Nagiua Cuomo-Haymour, Giorgio Bergamini, Giancarlo Russo, Luka Kulic, Irene Knuesel, Roland Martin, Andre Huss, Hayrettin Tumani, Markus Otto, Christopher R. Pryce
Summary: This study investigated the serum extracellular vesicle (EV) microRNAs (miRNAs) in different stages of multiple sclerosis (MS) patients and matched controls, aiming to identify MS stage-specific differential expressed miRNAs and their potential as biomarkers and relevance to the disease. The study found a moderate number of dysregulated serum EV miRNAs in CIS-remission and RRMS-relapse patients, with some miRNAs having potential as biomarkers for patient-control and CIS-RRMS differentiation. In silico analysis identified biological processes related to MS pathophysiology as the mRNA targets of RRMS-relapse-specific EV miRNAs. The findings demonstrate the potential of specific serum EV miRNAs as MS stage-specific biomarkers and provide insights into potential therapeutic targets.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Biochemistry & Molecular Biology
Josefine Ruder, Gianna Dinner, Aleksandra Maceski, Ernesto Berenjeno-Correa, Antonia Maria Mueller, Ilijas Jelcic, Jens Kuhle, Roland Martin
Summary: Autologous hematopoietic stem cell transplantation (aHSCT) is an effective treatment for multiple sclerosis (MS), which normalizes pathological processes and enhances beneficial processes. Biomarker analysis of MS patients undergoing aHSCT showed that serum levels of CXCL10, NfL, and GFAP significantly increased one month after transplantation, but returned to normal after one to two years. Levels of GFAP in cerebrospinal fluid (CSF) increased 24 months after aHSCT, indicating sustained astroglia activation. Other CSF markers remained relatively stable.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Hongbo Wang, Wei Wei, Jing-Ping Zhang, Zhihui Song, Yangyang Li, Wenming Xiao, Yijun Liu, Mu-Sheng Zeng, Michael N. Petrus, Craig J. Thomas, Marshall E. Kadin, Masao Nakagawa, Thomas A. Waldmann, Yibin Yang
Summary: Aberrant activation of NF-kappa B is a key oncogenic mechanism in B-cell lymphoma, while its role in anaplastic large cell lymphomas (ALCL) remains unclear. Study on ALCL cell line models revealed supporting roles of NFKB2 and NIK pathway, with STAT3 identified as the major mediator for NIK-dependent NF-kappa B activation in ALCL. The findings suggest potential benefits of combined NIK and JAK inhibitor therapy for NIK-positive ALK- ALCL with JAK/STAT3 somatic mutations.
Article
Cell Biology
Sigrid Dubois, Thomas A. Waldmann, Jurgen R. Muller
CELLULAR IMMUNOLOGY
(2020)